journal article·2014-10Open access

Development and characterization of stable nanovesicular carrier for drug delivery

Praveen Kumar Gaur, Suresh Purohit, Yatendra Kumar, Shikha Mishra, Anil Bhandari

Abstract

Lipid vesicles are an important drug carrier which can serve for controlled delivery of drugs; however, these vesicles are quite unstable at ambient temperature and require stringent storage condition. Present work was done to develop a stable vesicular system for drug delivery. Vesicles of ceramide-2, cholesterol, cholesterol sulfate, and palmitic acid were prepared and compared with phosphatidylcholine vesicles for physicochemical parameters and accelerated stability. Diclofenac sodium was used as a model drug. Based on physicochemical parameter and in vitro release PCV-3 and CV-3 were selected for further studies in three different accelerated stability conditions. PCV-3 showed moderate changes at 4°C but was severely affected at 25°C and 40°C. CV-3 showed stable characteristics at 4°C and 25°C whereas at 40°C, CV-3 showed signs of slight modification owing to moisture absorption. Based on the study, CV-3 containing highest content of palmitic acid was found to be most stable.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. 10.1080/0193269070171873510.1080/01932690701718735 ↗
2. 10.3109/10731199.2011.62228110.3109/10731199.2011.622281 ↗
3. Arifin DR · Artif Cells Blood Substit Immobil Biotechnol · 2005 · 33 · 11310.1081/BIO-200055874 ↗
4. 10.1111/j.2042-7158.1985.tb04990.x10.1111/j.2042-7158.1985.tb04990.x ↗
5. Baydoun L · Eur J Pharmaceut Biopharm · 2003 · 56 · 7310.1016/S0939-6411(03)00036-5 ↗
6. Blume G · J Liposome Research · 1992 · 2 · 35510.3109/08982109209010214 ↗
7. Dragicevic-Curic N · J Control Rel · 2008 · 127 · 5910.1016/j.jconrel.2007.12.013 ↗
8. 10.3109/0363904090341030010.3109/03639040903410300 ↗
9. 10.3109/21691401.2013.80008110.3109/21691401.2013.800081 ↗
10. Gaur PK · Pharmaceut Dev Tech · 2014 · 19 · 4810.3109/10837450.2012.751406 ↗
11. Goñi FM · . Biochim Biophys Acta · 2006 · 1758 · 190210.1016/j.bbamem.2006.09.011 ↗
12. 10.1016/S0378-5173(01)00896-110.1016/S0378-5173(01)00896-1 ↗
13. Kostarelos K · Adv Colloid Interface Sci · 2003 · 106 · 14710.1016/S0001-8686(03)00109-X ↗
14. Li X · Macromolecul Rapid Comm · 2007 · 28 · 66010.1002/marc.200600723 ↗
15. Lintner K · Int J Cosmetic Sci · 1997 · 19 · 1510.1111/j.1467-2494.1997.tb00162.x ↗
16. Liu D · J Nanopart Res · 2011 · 13 · 237510.1007/s11051-010-9998-y ↗
17. Moore DJ · Acta Dermatologica Venereol Supp · 2000 · 208 · 16
18. 10.1080/0265204080205541110.1080/02652040802055411 ↗
19. Sinico C · J Control Rel · 2005 · 103 · 12310.1016/j.jconrel.2004.11.020 ↗
20. Touitou E · J Control Rel · 2000 · 65 · 40310.1016/S0168-3659(99)00222-9 ↗
21. Walters KA · Transdermal and Dermatological Formulations · 2002 · 110.1201/9780824743239.ch1 ↗
22. Wartewig S · Skin Pharmacol Physiol · 2007 · 20 · 22010.1159/000104420 ↗
23. Weber TM · J Clin Aesthet Dermatol · 2012 · 5 · 29
24. Wertz PW · J Inves Dermatol · 1986 · 87 · 58210.1111/1523-1747.ep12455832 ↗
25. Yadav AV · Ind J Pharm Edu Res · 2011 · 45 · 402
26. 10.1016/0163-7258(81)90006-110.1016/0163-7258(81)90006-1 ↗
27. Zheng S · Biomater Artif Cells Immobilization Biotechnol · 1992 · 20 · 35510.3109/10731199209119655 ↗